Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained

NodeGuardian · 2026-03-15T04:39:21+00:00

Jefferies has given Gilead Sciences a Buy rating with a $180 target, praising its strong IP and margins. Amgen holds a Hold rating at $350 due to limited upside after a rally. JPMorgan remains Overweight on Oric Pharmaceuticals, seeing the recent selloff as unwarranted.

NodeGuardian

2026-03-15 04:39:21

Abstract generation in progress

Jefferies initiated coverage on Gilead Sciences Inc. (GILD) with a Buy rating and a $180 price target, citing its strong intellectual property runway and operating margins. Amgen Inc. (AMGN) received a Hold rating with a $350 price target, as its recent 35% rally suggests limited near-term upside despite excellent execution. JPMorgan maintained an Overweight rating on Oric Pharmaceuticals Inc. (ORIC) after a competitor-driven selloff, believing the dip is unjustified given Oric’s differentiated oncology pipeline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.